12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MK-3475: Phase Ib data

Interim data from 85 evaluable patients with advanced melanoma in an open-label Phase Ib trial showed that MK-3475 for >=12 weeks led to 43 objective responses, including 8 complete responses. In 27 patients previously treated with ...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >